To the Editor: As discussed in the Study Design and Practice Guideline sections of the
article, the guideline was introduced at the outset of the study period and revisited each …

To the Editor: As discussed in the Study Design and Practice Guideline sections of the
article, the guideline was introduced at the outset of the study period and revisited each …

To the Editor: We appreciate the attention of Drs. Dobie, Schneider, and Ferrer regarding our
article on teaching information mastery. We agree with their critique of our work to date. Our …

Background: While the use of angiotensin-converting enzyme (ACE) inhibitors for patients
with congestive heart failure (CHF) is supported by the results of clinical trials and expert …

Background: Angiotensin‐converting enzyme (ACE) inhibitors were underprescribed for
patients with congestive heart failure (CHF) treated in the community setting in the early …

A key Medicare quality measure is therapy with an angiotensin-converting enzyme inhibitor
(ACEI) in patients with heart failure at the time of hospital discharge. Butler and colleagues 1 …

Chronic heart failure, which affects 1 to 2 million Americans, is now the leading discharge
diagnosis among Medicare patients. Numerous guidelines state clearly that patients with left …

Randomized clinical trails have demonstrated that angiotensin-converting enzyme (ACE)
inhibitors reduce mortality, improve symptoms, and decrease hospitalization rates in …

To the Editor: We appreciate the attention of Drs. Dobie, Schneider, and Ferrer regarding our
article on teaching information mastery. We agree with their critique of our work to date. Our …

Because they provide relief of symptoms and reduce mortality, angiotensin-converting
enzyme (ACE) inhibitors have become a highly recommended part of the pharmacologic …